NASDAQ:BCYC

Bicycle Therapeutics Competitors

$28.38
-3.90 (-12.08 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$28.28
Now: $28.38
$33.20
50-Day Range
$22.40
MA: $26.69
$32.28
52-Week Range
$12.54
Now: $28.38
$33.20
Volume488,353 shs
Average Volume185,459 shs
Market Capitalization$655.29 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.21

Competitors

Bicycle Therapeutics (NASDAQ:BCYC) Vs. ITCI, ALXO, LGND, GBT, DCPH, and RCKT

Should you be buying BCYC stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Bicycle Therapeutics, including Intra-Cellular Therapies (ITCI), ALX Oncology (ALXO), Ligand Pharmaceuticals (LGND), Global Blood Therapeutics (GBT), Deciphera Pharmaceuticals (DCPH), and Rocket Pharmaceuticals (RCKT).

Bicycle Therapeutics (NASDAQ:BCYC) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, dividends, risk and institutional ownership.

Analyst Recommendations

This is a summary of current ratings for Bicycle Therapeutics and Intra-Cellular Therapies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bicycle Therapeutics00403.00
Intra-Cellular Therapies00703.00

Bicycle Therapeutics presently has a consensus target price of $38.00, suggesting a potential upside of 33.90%. Intra-Cellular Therapies has a consensus target price of $47.4286, suggesting a potential upside of 49.66%. Given Intra-Cellular Therapies' higher probable upside, analysts clearly believe Intra-Cellular Therapies is more favorable than Bicycle Therapeutics.

Institutional & Insider Ownership

42.7% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 79.1% of Intra-Cellular Therapies shares are owned by institutional investors. 26.3% of Bicycle Therapeutics shares are owned by company insiders. Comparatively, 18.2% of Intra-Cellular Therapies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Bicycle Therapeutics and Intra-Cellular Therapies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bicycle Therapeutics$13.80 million47.49$-30,610,000.00($2.77)-10.25
Intra-Cellular Therapies$60,000.0042,737.66$-147,720,000.00($2.68)-11.82

Bicycle Therapeutics has higher revenue and earnings than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Bicycle Therapeutics has a beta of -0.21, indicating that its share price is 121% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500.

Profitability

This table compares Bicycle Therapeutics and Intra-Cellular Therapies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bicycle Therapeutics-321.26%-42.73%-28.77%
Intra-Cellular Therapies-1,985.32%-48.27%-42.56%

Summary

Intra-Cellular Therapies beats Bicycle Therapeutics on 7 of the 13 factors compared between the two stocks.

ALX Oncology (NASDAQ:ALXO) and Bicycle Therapeutics (NASDAQ:BCYC) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.

Analyst Ratings

This is a summary of current recommendations and price targets for ALX Oncology and Bicycle Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ALX Oncology00703.00
Bicycle Therapeutics00403.00

ALX Oncology currently has a consensus target price of $90.6667, suggesting a potential upside of 42.18%. Bicycle Therapeutics has a consensus target price of $38.00, suggesting a potential upside of 33.90%. Given ALX Oncology's higher probable upside, research analysts clearly believe ALX Oncology is more favorable than Bicycle Therapeutics.

Insider and Institutional Ownership

73.5% of ALX Oncology shares are owned by institutional investors. Comparatively, 42.7% of Bicycle Therapeutics shares are owned by institutional investors. 26.3% of Bicycle Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares ALX Oncology and Bicycle Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ALX OncologyN/AN/AN/AN/AN/A
Bicycle Therapeutics$13.80 million47.49$-30,610,000.00($2.77)-10.25

ALX Oncology has higher earnings, but lower revenue than Bicycle Therapeutics.

Profitability

This table compares ALX Oncology and Bicycle Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ALX OncologyN/AN/AN/A
Bicycle Therapeutics-321.26%-42.73%-28.77%

Summary

ALX Oncology beats Bicycle Therapeutics on 6 of the 8 factors compared between the two stocks.

Ligand Pharmaceuticals (NASDAQ:LGND) and Bicycle Therapeutics (NASDAQ:BCYC) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.

Analyst Ratings

This is a summary of current recommendations and price targets for Ligand Pharmaceuticals and Bicycle Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ligand Pharmaceuticals01502.83
Bicycle Therapeutics00403.00

Ligand Pharmaceuticals currently has a consensus target price of $215.60, suggesting a potential upside of 40.51%. Bicycle Therapeutics has a consensus target price of $38.00, suggesting a potential upside of 33.90%. Given Ligand Pharmaceuticals' higher probable upside, research analysts clearly believe Ligand Pharmaceuticals is more favorable than Bicycle Therapeutics.

Insider and Institutional Ownership

42.7% of Bicycle Therapeutics shares are owned by institutional investors. 10.6% of Ligand Pharmaceuticals shares are owned by insiders. Comparatively, 26.3% of Bicycle Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Ligand Pharmaceuticals and Bicycle Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ligand Pharmaceuticals$120.28 million21.19$629.30 million$2.1172.72
Bicycle Therapeutics$13.80 million47.49$-30,610,000.00($2.77)-10.25

Ligand Pharmaceuticals has higher revenue and earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Ligand Pharmaceuticals has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of -0.21, indicating that its stock price is 121% less volatile than the S&P 500.

Profitability

This table compares Ligand Pharmaceuticals and Bicycle Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ligand Pharmaceuticals-11.23%5.90%3.22%
Bicycle Therapeutics-321.26%-42.73%-28.77%

Summary

Ligand Pharmaceuticals beats Bicycle Therapeutics on 9 of the 14 factors compared between the two stocks.

Global Blood Therapeutics (NASDAQ:GBT) and Bicycle Therapeutics (NASDAQ:BCYC) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.

Analyst Ratings

This is a summary of current recommendations and price targets for Global Blood Therapeutics and Bicycle Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Global Blood Therapeutics051302.72
Bicycle Therapeutics00403.00

Global Blood Therapeutics currently has a consensus target price of $92.3333, suggesting a potential upside of 126.47%. Bicycle Therapeutics has a consensus target price of $38.00, suggesting a potential upside of 33.90%. Given Global Blood Therapeutics' higher probable upside, research analysts clearly believe Global Blood Therapeutics is more favorable than Bicycle Therapeutics.

Insider and Institutional Ownership

42.7% of Bicycle Therapeutics shares are owned by institutional investors. 4.3% of Global Blood Therapeutics shares are owned by insiders. Comparatively, 26.3% of Bicycle Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Global Blood Therapeutics and Bicycle Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Global Blood Therapeutics$2.11 million1,201.01$-266,770,000.00($4.71)-8.66
Bicycle Therapeutics$13.80 million47.49$-30,610,000.00($2.77)-10.25

Bicycle Therapeutics has higher revenue and earnings than Global Blood Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Global Blood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Global Blood Therapeutics has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of -0.21, indicating that its stock price is 121% less volatile than the S&P 500.

Profitability

This table compares Global Blood Therapeutics and Bicycle Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Global Blood Therapeutics-332.94%-56.43%-39.32%
Bicycle Therapeutics-321.26%-42.73%-28.77%

Summary

Bicycle Therapeutics beats Global Blood Therapeutics on 9 of the 14 factors compared between the two stocks.

Deciphera Pharmaceuticals (NASDAQ:DCPH) and Bicycle Therapeutics (NASDAQ:BCYC) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.

Profitability

This table compares Deciphera Pharmaceuticals and Bicycle Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Deciphera PharmaceuticalsN/A-45.02%-40.12%
Bicycle Therapeutics-321.26%-42.73%-28.77%

Analyst Ratings

This is a summary of current recommendations and price targets for Deciphera Pharmaceuticals and Bicycle Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Deciphera Pharmaceuticals03702.70
Bicycle Therapeutics00403.00

Deciphera Pharmaceuticals currently has a consensus target price of $70.30, suggesting a potential upside of 60.47%. Bicycle Therapeutics has a consensus target price of $38.00, suggesting a potential upside of 33.90%. Given Deciphera Pharmaceuticals' higher probable upside, research analysts clearly believe Deciphera Pharmaceuticals is more favorable than Bicycle Therapeutics.

Valuation and Earnings

This table compares Deciphera Pharmaceuticals and Bicycle Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Deciphera Pharmaceuticals$25 million100.98$-192,260,000.00($4.48)-9.78
Bicycle Therapeutics$13.80 million47.49$-30,610,000.00($2.77)-10.25

Bicycle Therapeutics has lower revenue, but higher earnings than Deciphera Pharmaceuticals. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Deciphera Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Deciphera Pharmaceuticals has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of -0.21, indicating that its stock price is 121% less volatile than the S&P 500.

Insider and Institutional Ownership

73.6% of Deciphera Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.7% of Bicycle Therapeutics shares are owned by institutional investors. 7.0% of Deciphera Pharmaceuticals shares are owned by insiders. Comparatively, 26.3% of Bicycle Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Deciphera Pharmaceuticals beats Bicycle Therapeutics on 8 of the 14 factors compared between the two stocks.

Rocket Pharmaceuticals (NASDAQ:RCKT) and Bicycle Therapeutics (NASDAQ:BCYC) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, risk, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Rocket Pharmaceuticals and Bicycle Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rocket PharmaceuticalsN/A-35.81%-27.52%
Bicycle Therapeutics-321.26%-42.73%-28.77%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Rocket Pharmaceuticals and Bicycle Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rocket Pharmaceuticals011302.93
Bicycle Therapeutics00403.00

Rocket Pharmaceuticals currently has a consensus price target of $59.1818, suggesting a potential upside of 50.17%. Bicycle Therapeutics has a consensus price target of $38.00, suggesting a potential upside of 33.90%. Given Rocket Pharmaceuticals' higher probable upside, equities analysts plainly believe Rocket Pharmaceuticals is more favorable than Bicycle Therapeutics.

Valuation & Earnings

This table compares Rocket Pharmaceuticals and Bicycle Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rocket PharmaceuticalsN/AN/A$-77,270,000.00($1.58)-24.94
Bicycle Therapeutics$13.80 million47.49$-30,610,000.00($2.77)-10.25

Bicycle Therapeutics has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Rocket Pharmaceuticals has a beta of 2.05, indicating that its stock price is 105% more volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of -0.21, indicating that its stock price is 121% less volatile than the S&P 500.

Insider & Institutional Ownership

42.7% of Bicycle Therapeutics shares are owned by institutional investors. 41.4% of Rocket Pharmaceuticals shares are owned by insiders. Comparatively, 26.3% of Bicycle Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Rocket Pharmaceuticals beats Bicycle Therapeutics on 8 of the 13 factors compared between the two stocks.


Bicycle Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.69-0.6%$2.56 billion$60,000.00-9.84News Coverage
ALX Oncology logo
ALXO
ALX Oncology
1.9$63.77-13.2%$2.56 billionN/A0.00Analyst Report
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$153.44-1.4%$2.55 billion$120.28 million-154.99Analyst Upgrade
News Coverage
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.77-1.1%$2.53 billion$2.11 million-8.82Analyst Upgrade
News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$43.81-1.4%$2.52 billion$25 million-8.76Insider Selling
News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$39.41-8.7%$2.43 billionN/A-21.65News Coverage
Gap Down
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.19-0.9%$2.43 billion$182.24 million-7.99News Coverage
Cryoport logo
CYRX
Cryoport
1.9$52.29-3.1%$2.38 billion$33.94 million-90.16Insider Selling
News Coverage
Gap Down
Xencor logo
XNCR
Xencor
1.2$40.47-2.9%$2.35 billion$156.70 million-28.91News Coverage
Gap Down
Amarin logo
AMRN
Amarin
1.6$5.93-1.2%$2.33 billion$429.76 million-118.58
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$31.30-1.3%$2.22 billion$15 million-16.39
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$43.75-0.5%$2.18 billion$963.01 million13.59Analyst Upgrade
News Coverage
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$68.49-16.4%$2.10 billionN/A-29.14Insider Selling
Gap Down
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.13-1.4%$2.01 billion$410,000.00-6.12
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.09-1.3%$1.99 billion$23.90 million-16.20Analyst Revision
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.99-2.1%$1.98 billionN/A-19.70
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.43-3.8%$1.95 billion$103.54 million-19.12Gap Down
MORF
Morphic
1.1$59.35-3.0%$1.93 billion$16.98 million-38.04Insider Selling
Gap Down
Kura Oncology logo
KURA
Kura Oncology
1.6$28.57-0.8%$1.89 billionN/A-17.53
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.58-0.1%$1.88 billion$34.51 million-17.59News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02-0.4%$1.88 billionN/A-10.57
MacroGenics logo
MGNX
MacroGenics
1.2$31.16-1.3%$1.87 billion$64.19 million-9.96News Coverage
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$5.96-2.7%$1.79 billion$1.63 billion14.54News Coverage
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$37.94-0.1%$1.77 billion$14.87 million-14.16News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$48.93-21.0%$1.72 billionN/A0.00Insider Buying
High Trading Volume
Gap Down
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.16-0.1%$1.72 billion$26.87 million-12.65
FibroGen logo
FGEN
FibroGen
1.8$18.57-1.3%$1.70 billion$256.58 million-7.11Analyst Downgrade
High Trading Volume
Unusual Options Activity
Analyst Revision
News Coverage
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$41.57-1.3%$1.66 billionN/A-173.21
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.99-7.6%$1.65 billion$2.34 million-10.17Gap Down
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.15-1.2%$1.65 billionN/A-6.46Insider Selling
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$35.26-6.0%$1.64 billionN/A0.00Insider Selling
News Coverage
Gap Down
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.19-1.5%$1.64 billion$428.41 million14.77
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.80-1.3%$1.63 billion$320,000.00-8.71Analyst Report
News Coverage
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.32-0.2%$1.61 billionN/A0.00
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$25.61-1.4%$1.55 billion$175.34 million-15.06
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.8$37.41-13.5%$1.54 billionN/A0.00Insider Selling
Gap Down
Generation Bio logo
GBIO
Generation Bio
1.8$27.20-5.3%$1.53 billionN/A0.00Insider Selling
News Coverage
Gap Down
Kronos Bio logo
KRON
Kronos Bio
1.7$27.28-0.3%$1.53 billionN/A0.00Lockup Expiration
News Coverage
uniQure logo
QURE
uniQure
1.7$33.74-5.2%$1.52 billion$7.28 million-8.95Gap Down
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$16.60-4.0%$1.52 billion$145.97 million-6.72News Coverage
Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.56-3.8%$1.51 billion$82.27 million-18.44Unusual Options Activity
News Coverage
Gap Down
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$28.96-0.4%$1.50 billion$4.23 million-21.45
ATBPD
Antibe Therapeutics
0.1$3.88-0.5%$1.50 billion$7.51 million-6.46Gap Down
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.4$28.31-0.7%$1.50 billion$392.76 million11.75Analyst Revision
News Coverage
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$33.30-2.3%$1.49 billionN/A0.00Insider Selling
News Coverage
Gap Down
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$29.19-5.9%$1.46 billion$19.89 million-13.77Unusual Options Activity
News Coverage
Gap Up
Zymeworks logo
ZYME
Zymeworks
1.8$31.00-1.5%$1.43 billion$29.54 million-8.22News Coverage
Endo International logo
ENDP
Endo International
1.3$6.20-1.0%$1.43 billion$2.91 billion-9.12Analyst Report
News Coverage
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.80-1.5%$1.42 billion$6.20 million-14.39News Coverage
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.